Lysosomes are often described as the recycling centers of the cell. These acidic, membrane-bound compartments contain a cocktail of degradative enzymes capable of breaking down proteins, lipids, damaged organelles, and other cellular debris into their basic building blocks, which can then be reused. Because nearly every cellular waste stream ultimately passes through the lysosome, even partial impairment of these organelles can cascade into widespread dysfunction. Lysosomal damage is a hallmark of aging, neurodegenerative disease, and ischemia-reperfusion injury, the tissue damage that occurs when blood supply returns to tissue after a period of oxygen deprivation. Yet despite decades of research into lysosome biology, the mechanisms that maintain lysosomal integrity under stress have remained incompletely understood.

The prevailing models of lysosomal maintenance have centered on autophagic lysosome reformation, a process in which lysosomal components are salvaged from autolysosomes, hybrid compartments formed when autophagosomes fuse with lysosomes, and reassembled into new functional lysosomes. The new study demonstrates that B-fission operates independently of this canonical pathway. When lysosomes are damaged by hypoxia-reoxygenation stress, they do not simply wait to be recycled through autophagy. Instead, they actively participate in their own rescue, generating membrane buds on their surface. These buds progressively extend from the parent organelle and then undergo scission, pinching off to yield small, fully functional lysosomes. The undamaged components of the impaired parent organelle are thereby reorganized into daughter organelles, leaving the damaged material behind to be dealt with separately.

The mechanistic heart of the discovery lies in the identity of the scission machinery. Budding and fission events in cells generally require a specific set of proteins to constrict and sever a membrane neck. For mitochondria, that machinery is well known: the dynamin-related GTPase DRP1, recruited to the mitochondrial outer membrane by adaptor proteins such as MFF, constricts and divides mitochondria during mitochondrial fission. The researchers found that damaged lysosomes co-opt this exact mitochondrial division apparatus. MFF, a fission adaptor normally resident on mitochondria, is delivered to lysosomes, where it recruits DRP1 to drive the scission of the budding lysosomal membrane. In other words, the cell repurposes the mitochondrial division machinery to divide a completely different organelle.

How does MFF get to lysosomes in the first place? The answer involves mitochondrial-derived vesicles, or MDVs. These small vesicles bud from mitochondria and are known to transport selected mitochondrial cargo to other cellular destinations, most notably to peroxisomes and to autophagosomes during mitophagy. The new work shows that under hypoxia-reoxygenation stress, mitochondria generate MDVs carrying MFF. These MFF-positive vesicles then travel to damaged lysosomes and deliver their cargo, providing the adaptor that lysosomes need to assemble a functional DRP1-dependent scission apparatus. This is a striking example of organelle-to-organelle communication, with mitochondria effectively supplying the tools that allow lysosomes to renew themselves.

Two additional proteins complete the regulatory circuit. The first is MIRO2, a mitochondrial outer-membrane GTPase better known for its role in linking mitochondria to microtubule-dependent motor proteins and regulating mitochondrial motility. The study shows that MIRO2 promotes the formation of MFF-positive MDVs through a direct physical interaction with MFF, acting as a gatekeeper that selects MFF as cargo for vesicular export. The second is ITM2C, a lysosomal membrane protein that binds MIRO2. By tethering the MFF-carrying vesicles to the lysosomal surface, ITM2C guides and anchors them at the correct destination, ensuring efficient MFF delivery and, consequently, efficient B-fission. The researchers describe this stress-responsive pathway as the ITM2C–MIRO2–MFF–DRP1 axis, a chain of interactions that connects the mitochondrial surface to the lysosomal scission machinery.

The physiological relevance of this pathway was demonstrated through manipulation of AMPK, the AMP-activated protein kinase, a master metabolic sensor that is activated when cellular energy levels fall. When cells were treated with AMPK activators such as 991 or metformin under normal oxygen conditions, MFF-dependent lysosomal B-fission was promoted, indicating that AMPK is a physiological trigger for the pathway. Conversely, when AMPK was inhibited with dorsomorphin during hypoxia-reoxygenation, B-fission was suppressed, and lysosomes presumably remained in their damaged state. This pharmacological control establishes AMPK as a central node that couples energy stress to lysosomal renewal, and it raises the intriguing possibility that widely used drugs such as metformin may partially exert their protective effects by boosting this lysosome-repair program.

The implications of the work extend across multiple fields. For researchers studying ischemia-reperfusion injury, the identification of a stress-activated lysosomal renewal pathway offers a mechanistic explanation for why lysosomal damage is so consequential during heart attack and stroke, and it suggests that enhancing B-fission pharmacologically could protect vulnerable tissues. For the lysosome biology community, the finding adds a new mode of organelle maintenance to the established repertoire of autophagic lysosome reformation and endosomal sorting. And for cell biologists more broadly, the demonstration that MDVs can ferry a fission adaptor between organelles, and that a mitochondrial division machine can be installed on lysosomes, underscores how fluid the boundaries between organelle systems really are. Mitochondria, long appreciated as signaling hubs that communicate through calcium, reactive oxygen species, and metabolites, now appear to communicate through physical transport of division machinery as well.

The technical elegance of the study lies in its dissection of each step of the pathway. By showing that MIRO2 binds MFF directly, that MDVs carry MFF, that ITM2C tethers those vesicles to lysosomes, and that DRP1 recruitment to MFF-decorated lysosomes is required for scission, the authors built a complete causal chain from mitochondrial membrane to lysosomal division. Disrupting any single link, whether by removing MIRO2, ITM2C, MFF, or DRP1, or by blocking AMPK signaling, compromises the ability of stressed cells to regenerate functional lysosomes from damaged parents. Conversely, activating AMPK under baseline conditions is sufficient to initiate the program even without hypoxic stress.

What remains to be explored is the breadth of this phenomenon. Hypoxia-reoxygenation is a particularly well-defined stress, but lysosomal damage arises in many contexts, including exposure to aggregate-prone proteins in neurodegeneration, lipid overload in metabolic disease, and the normal wear of aging. Whether B-fission operates in neurons, in cardiomyocytes, and in aging tissues in vivo are pressing questions. There is also the tantalizing therapeutic prospect that metformin, already one of the most prescribed drugs in the world, could be repurposed or optimized to strengthen lysosomal quality control in diseases of lysosomal stress. For now, the study stands as a vivid demonstration that the cell’s repair strategies are more inventive than previously imagined: when a lysosome is damaged, the mitochondria deliver the scissors that let it cut its losses and begin again.

The research, led by Antonella Izzo of Federico II University in Naples, Italy, together with colleagues at the National Research Council of Italy and the Telethon Institute of Genetics and Medicine, focused on human trisomic fetal fibroblasts, skin-derived cells obtained from fetuses with Down syndrome. By performing an integrated characterization of the autophagy–mitophagy–lysosome axis in these cells, the team uncovered a paradox that had clouded earlier analyses: trisomic cells simultaneously display elevated levels of autophagy and mitophagy markers while failing to actually clear their damaged mitochondria. The machinery, in other words, appears to be running at full throttle yet accomplishing far less than it should — a signature of saturation rather than simple inactivity.

At the molecular level, the trisomic fibroblasts showed increased steady-state abundance of the key proteins that orchestrate mitochondrial quality control, including PINK1 and PARKIN, the two central players of the canonical mitophagy pathway, as well as their downstream adaptors OPTN and NDP52, which physically link marked mitochondria to the autophagic engulfment machinery. Levels of LC3-II and p62, hallmarks of autophagosome formation and cargo recruitment, were likewise elevated. On the surface, this looks like a robust response to mitochondrial damage. But functional assays told a different story. The cells accumulated autophagic vacuoles, exhibited reduced autophagic flux — meaning the flow of material through the degradation pipeline was slowed — and showed impaired delivery of mitochondria to lysosomes, the final and most consequential step of the disposal process.

This combination of findings supports a model in which the extra chromosome imposes a chronic proteostatic burden. Trisomy 21 doesn’t merely add one gene’s worth of product; it shifts the dosage of hundreds of genes, flooding the cell with surplus proteins and stressing organelles across the board. In this environment, the mitochondrial quality control system becomes clogged, much like a conveyor belt that keeps accepting packages faster than the warehouse at the end can process them. Autophagic structures pile up, damaged mitochondria linger, and the cell’s energy economy and stress defenses degrade accordingly. The researchers argue that this pathway saturation is a key pathogenetic mechanism in trisomic cells, and by extension a contributor to the developmental and physiological abnormalities associated with Down syndrome.

The therapeutic twist of the study centers on metformin, a biguanide derived from the French lilac that has been a first-line treatment for type 2 diabetes for decades and has more recently attracted intense interest for its effects on aging and metabolism. Metformin’s best-known molecular action is the activation of AMPK and the attenuation of mTOR-associated signaling. mTOR, the mechanistic target of rapamycin, is the master brake on autophagy; when it is active, the cell prioritizes growth over recycling. By dampening mTOR signaling, metformin effectively releases that brake, allowing autophagy to proceed more freely.

In the trisomic fibroblasts, metformin treatment produced a striking normalization across multiple components of the mitochondrial quality control pathway. The drug enhanced autophagic flux, easing the logjam that had trapped material in autophagic vacuoles, and brought mitophagy-related protein levels back toward baseline — an apparent paradox resolved by the understanding that elevated marker proteins in saturated cells reflect accumulated, undegraded machinery rather than heightened activity. With the pathway flowing again, the excess tags and adaptors get cleared along with the cargo, and steady-state levels settle to healthy values.

Crucially, the team documented a rescue at the level of the lysosome itself, the acidic terminal compartment where mitochondria and other cellular refuse are ultimately destroyed. Metformin increased the physical association between mitochondria and lysosomes, suggesting improved contact and hand-off between the two organelles — a step that was measurably impaired in untreated trisomic cells. The drug also restored lysosomal degradative competence, as demonstrated by increased DQ-BSA activity, a fluorescent proteolysis assay in which degradation of a labeled substrate releases a bright signal only if the lysosome can actually digest it. In addition, metformin promoted the maturation of Cathepsin D, a key lysosomal protease that must be proteolytically processed into its active form for the organelle to function. Together, these results indicate that metformin doesn’t just push more cargo toward the lysosome; it also sharpens the degradative machinery waiting at the end of the line.

The implications extend well beyond the fibroblast dish. Down syndrome affects roughly one in every 700 births worldwide, and individuals with the condition experience accelerated aspects of biological aging, including earlier onset of Alzheimer-like neuropathology, increased oxidative stress, and compromised immune function. Many of these features have been linked, at least in part, to mitochondrial dysfunction. If saturated mitophagy is a genuine driver of that dysfunction, then interventions that relieve the bottleneck — whether pharmacological or otherwise — could in principle ameliorate a broad swath of Down syndrome pathology. Metformin, already proven safe in millions of patients over decades of clinical use, would be an unusually attractive candidate for translation, though the current study is confined to cultured cells and any clinical application would require carefully designed trials.

The work also fits into a broader conceptual shift in how scientists understand aneuploidy — the presence of an abnormal number of chromosomes. Rather than viewing trisomy as a collection of gene-by-gene dosage effects, an emerging model treats it as a systemic insult: an extra chromosome imposes a chronic burden on protein homeostasis, the proteostasis network, and organelle quality control systems that must cope with the resulting overload. Under this framing, the defects seen in Down syndrome cells — from impaired autophagic flux to stressed lysosomes — are downstream consequences of a capacity problem, not necessarily primary failures of any single pathway. This explains why boosting individual components of the system may be insufficient, and why approaches that increase overall throughput, as metformin appears to do, may be more effective.

Methodologically, the study stands out for the breadth of its integrated analysis. Rather than relying on a single readout, the investigators triangulated across the entire disposal pipeline: marker protein quantification by immunoblotting, morphological assessment of autophagic vacuole accumulation, functional flux measurements, visualization of mitochondria–lysosome contacts, lysosomal enzymatic activity assays, and maturation analysis of Cathepsin D. This multi-pronged approach was essential to distinguishing a saturated but structurally intact pathway from a simply deficient one — a distinction with very different therapeutic implications. A pathway that is overwhelmed can be un-clogged; a pathway that is broken must be rebuilt.

The researchers acknowledge that their study was conducted in fetal fibroblasts, which, while a valuable and ethically accessible human trisomic model, differ in important respects from neurons and other cell types central to Down syndrome pathology. Whether metformin exerts the same restorative effects on the mitophagy–lysosome axis in the brain, where mitochondrial dysfunction contributes most visibly to cognitive outcomes, remains an open and pressing question. Prior work has linked mTOR hyperactivation in Down syndrome to deficits in autophagy induction and mitophagy, and the new findings both reinforce and refine that picture by pinpointing saturation and lysosomal incompetence as separable, drug-responsive nodes in the network.

What the study delivers, in the meantime, is a mechanistic reframing with immediate scientific value. Mitochondrial quality control in trisomy 21 is not absent — it is drowning. The cell detects its damaged mitochondria, tags them with PINK1 and PARKIN, recruits OPTN and NDP52, wraps them in LC3-decorated autophagosomes, and then stalls at the delivery and digestion stages. Metformin, by relieving mTOR-driven constraints and rejuvenating lysosomal competence, reopens the channel from tag to trash. In doing so, the drug transforms our picture of what is therapeutically possible in aneuploid cells and offers a testable path from a centuries-old herbal remedy to a modern tool against the cellular consequences of an extra chromosome.

The ER, a membrane-bound organelle often described as the cell’s protein factory, is where roughly one-third of all human proteins, including nearly 7,000 unique molecules, begin their complex folding journey. This environment is chaotic and crowded, filled with nascent polypeptides, folding enzymes, and molecular chaperones. Among these, chaperones function as specialized molecular guardians that assist proteins in reaching their native, functional conformations or, failing that, direct irreparably misfolded proteins toward degradation pathways. Defects in this quality control system can trigger a cascade of cellular malfunctions, implicated in diseases such as cystic fibrosis, emphysema, and Alzheimer’s.

Despite the vital role chaperones play, a fundamental question has persisted: how do these molecular caretakers discriminate between properly folded and misfolded proteins amidst the entropic sea of the ER lumen? The answer, as detailed by Hebert and his team, lies in a sophisticated carbohydrate-based “glyco-code” inscribed on proteins themselves via attachment of specialized sugar structures called N-glycans. These N-glycans act as molecular zip codes, precisely positioned on the protein’s surface, encoding vital information that directs the chaperone machinery’s interactions and decisions.

The concept of a glyco-code marks a paradigm shift from traditional views that have primarily focused on the polypeptide chain as the sole bearer of folding information. Instead, the review artfully illustrates how carbohydrate moieties, especially N-glycans, serve as dynamic modulators of protein destiny within the ER. This code utilizes sugar patterns, sugar-processing enzymes, and lectin chaperones—carbohydrate-binding proteins that can “read” the sugar code—to guide substrate folding, sorting, and degradation. The interplay between these elements ensures only correctly folded proteins proceed toward secretion or membrane integration, while aberrant proteins are sequestered or targeted for destruction.

Central to this glyco-code is the enzyme UDP-glucose:glycoprotein glucosyltransferase (UGGT), described in prior work involving Hebert’s research group and highlighted in the current review. UGGT functions as a folding sensor by recognizing misfolded regions and selectively reglucosylating N-glycans, thereby generating a recognizable signal for ER-resident lectin chaperones such as calnexin and calreticulin. These chaperones engage in cycles of binding and release, giving proteins multiple opportunities to achieve their native fold, a process critical to maintaining cellular proteostasis.

Moreover, the review elucidates the intricate biochemical pathways that regulate how N-glycans are attached co-translationally and post-translationally to asparagine residues within consensus sequences on nascent polypeptides. The precise positioning and structural diversity of these glycans significantly influence the affinity and specificity of chaperone interactions. This spatially encoded information facilitates compartmentalized maturation processes and ensures the fidelity of sorting mechanisms that traffic proteins from the ER to the Golgi apparatus and beyond.

A remarkable aspect highlighted is the dual role of the glyco-code: not only does it assist in protein folding quality control, but it also functions as an addressing system that dictates intracellular trafficking pathways. Lectin chaperones interpret the glyco-code to direct folded proteins toward their ultimate cellular destinations, whereas misfolded or unassembled proteins are recognized by ER-associated degradation (ERAD) machinery, which retrotranslocates them for cytosolic proteasomal degradation.

The work by Hebert, and elucidated by his last graduate student Kevin Guay, also stresses the implications for human health. Many protein conformational diseases are rooted in failures of this glyco-code-based quality control, where either the recognition or processing of N-glycans is impaired, leading to accumulation of toxic protein aggregates or loss of essential functional proteins. Therapeutic strategies targeting components of this glycosylation-dependent chaperone network are increasingly attractive for treating diseases linked to protein misfolding.

In essence, the review synthesizes decades of biochemical, structural, and cellular biology research into a comprehensive framework that redefines our understanding of how protein folding and quality control are intricately regulated by N-glycans. This new vision fosters a broader appreciation that genetic information encoded in DNA extends beyond sequence alone, encompassing a multilayered molecular code integrated within protein glycosylation patterns.

Hebert’s magnum opus not only honors his lifetime contributions to the field but also establishes a foundation upon which future studies will build, aiming to fully decipher the glyco-code. This, in turn, promises to unlock novel therapeutic avenues and advance our ability to manipulate protein folding processes in disease and biotechnology.

The collaborative nature of this work, involving UMass Amherst researchers and their deep expertise in enzymology, structural biology, and cellular machinery, stands as a testament to the enduring quest to unravel the complexities of life at the molecular level. As chaperone biology evolves, embracing the glyco-code paradigm will be pivotal in transforming molecular medicine and our grasp of cellular homeostasis.

With the publication of this comprehensive review in Nature Reviews Molecular Cell Biology, the scientific community gains critical insight into an elegant, carbohydrate-guided proofreading system. Ultimately, this work reinvents the classic narrative of genetic coding and protein folding by placing glycosylation—not just amino acid sequence—at the forefront of post-translational quality control.

Subject of Research: Protein folding quality control mediated by N-glycan-dependent chaperone systems within the endoplasmic reticulum.

Article Title: N-glycan-dependent protein maturation and quality control in the ER

Web References:
https://www.nature.com/articles/s41580-025-00855-y
http://dx.doi.org/10.1038/s41580-025-00855-y

Image Credits: UMass Amherst

Keywords: Protein folding, N-glycans, glyco-code, endoplasmic reticulum, molecular chaperones, UGGT, calnexin, calreticulin, ER-associated degradation, protein quality control, secretome, biochemistry, molecular biology